不同给药方法治疗细菌性阴道病对阴道微生态环境及免疫因子表达的影响

目的监测细菌性阴道病(BV)患者不同给药方法治疗前后阴道微生态恢复情况及局部免疫因子水平,探索药物选择与疗效转归的关系。方法选取健康女性25例为对照组,BV患者100例为治疗组。治疗组按随机数字表法分为A~D组,每组25例。A组甲硝唑阴道泡腾片;B组甲硝唑阴道泡腾片+乳杆菌活菌胶囊;C组硝呋太尔阴道片;D组硝呋太尔阴道片+乳杆菌活菌胶囊。A、C组均每晚给药1粒,共7d,B、D组两种药物按先后顺序分别每晚1粒给药7d,共14d。应用微生态评价体系及酶联免疫吸附法比较治疗组与对照组之间及各组BV患者治疗前后的临床疗效、阴道微生态重建及阴道灌洗液中白细胞介素-8(IL-8)、Toll样受体2(TLR...

Full description

Saved in:
Bibliographic Details
Published in天津医药 Vol. 44; no. 8; pp. 1029 - 1032
Main Author 王芳;霍彦;刘艳妍;尹利荣
Format Journal Article
LanguageChinese
Published 天津医科大学第二医院妇科 邮编300211%天津医科大学第二医院计划生育科 300211%天津华兴医院妇产科 2016
Subjects
Online AccessGet full text
ISSN0253-9896
DOI10.11958/20160162

Cover

More Information
Summary:目的监测细菌性阴道病(BV)患者不同给药方法治疗前后阴道微生态恢复情况及局部免疫因子水平,探索药物选择与疗效转归的关系。方法选取健康女性25例为对照组,BV患者100例为治疗组。治疗组按随机数字表法分为A~D组,每组25例。A组甲硝唑阴道泡腾片;B组甲硝唑阴道泡腾片+乳杆菌活菌胶囊;C组硝呋太尔阴道片;D组硝呋太尔阴道片+乳杆菌活菌胶囊。A、C组均每晚给药1粒,共7d,B、D组两种药物按先后顺序分别每晚1粒给药7d,共14d。应用微生态评价体系及酶联免疫吸附法比较治疗组与对照组之间及各组BV患者治疗前后的临床疗效、阴道微生态重建及阴道灌洗液中白细胞介素-8(IL-8)、Toll样受体2(TLR2)、肿瘤坏死因子-α(TNF-α)的水平。结果与对照组相比,治疗组均存在阴道菌群紊乱、pH值升高和微生态失调现象。治疗前,治疗组阴道灌洗液中IL-8水平与对照组差异无统计学意义,TNF-α及TLR2水平均高于对照组(P<0.05),各治疗组间免疫因子水平差异无统计学意义。治疗后,B、D组治疗有效率及阴道微生态恢复率均高于A、C组(P<0.05),IL-8水平与A、C组差异无统计学意义,TNF-α及TLR2水平均低于A、C组(P<0.05)。结论利用微生态评价系统辅助评判不同给药方案治疗BV效果证实硝呋太尔阴道片联合乳杆菌活菌胶囊序贯给药方案在临床疗效、阴道微生态重建及阴道局部免疫恢复方面优于传统甲硝唑单独给药治疗。
Bibliography:vaginosis, bacterial; lactobacillus; metronidazole; nifuratel; interleukin- 8; toll- like receptor 2; tumor necrosis factor-alpha
Objective Tracking of the vaginal microflora recovery and the expression of immune factors from untreated and treated patients with bacterial vaginosis (BV) by using different administration regimens and studying the relationship of treatment results and regimen selections. Methods 25 healthy females were selected as a control group and 100 BV patients were randomly divided into 4 groups (n=25/group). Group A: Intravaginal administration of metronidazole (×7 d),Group B: Continuous intravaginal administration of metronidazole (×7 d) and then live Lactobacillus Capsule (×7 d) , Group C: Intravaginal administration of nifuratel (×7 d), Group D: Continuous intravaginal administration of nifuratel (×7 d) and then live Lactobacillus Capsule (×7 d). The microecological assessment system and EILSA were used to compare the clinical efficacy, vaginal microflora recovery and the changes in IL-
ISSN:0253-9896
DOI:10.11958/20160162